Merck announced final results from a Phase III, open-label study designed to compare the impact of two anemia management strategies on sustained virologic response ( SVR ) in patients with chronic hepatitis C virus ( HCV ) genotype 1 infection treated with VICTRELIS  ( boceprevir ) in combination with PEGINTRON  ( peginterferon alfa-2b ) and ribavirin (P/R).